# Anika Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Anika Therapeutics, Inc.).

## Overview

Anika Therapeutics, Inc. develops hyaluronic acid-based orthopedic products focused on osteoarthritis pain management and regenerative solutions. The company was founded in 1992 and has built its business around proprietary HA technology used in injection therapies and implantable/regenerative orthopedic applications. In 2024-2025, Anika shifted its strategy to concentrate on its core OA Pain Management and Regenerative Solutions portfolios, including the divestiture of non-core businesses. Its commercial model combines direct selling in the U.S. for selected regenerative products with OEM and distributor partnerships, most notably with J&J MedTech for key OA products. The company serves clinicians, hospitals, ambulatory surgery centers, and distribution partners across the U.S. and international markets.

## Products & services

• OA Pain Management products: Monovisc, Orthovisc, Cingal
• Regenerative Solutions: Integrity Implant System, Hyalofast
• OEM-supplied orthopedic products for partners like J&J MedTech
• Direct commercial sales to hospitals, ASCs, and clinicians
• International distributor-based sales and market access support

- **OA Pain Management** (55%) — Viscosupplementation and related HA-based products used to treat osteoarthritis pain, primarily through office-based injections.
- **Regenerative Solutions** (25%) — Implantable and biologic orthopedic products designed to support tissue repair and joint preservation in surgical settings.
- **OEM Channel** (20%) — Products manufactured and supplied to partners such as J&J MedTech, which handle downstream marketing and distribution.

- OA Pain Management products such as Monovisc, Orthovisc, and Cingal
- Regenerative Solutions including Integrity and Hyalofast
- OEM channel supply for partner-branded orthopedic products
- Direct U.S. commercial sales for selected regenerative products
- International distribution and territory support through commercial partners
- Contract-based manufacturing and supply for OEM customers

## Customers

Anika sells through several distinct customer types, but a small number of large partners account for a substantial share of revenue. Its most important commercial relationship is with J&J MedTech, which represented 50% of revenue in 2025 and resells key OA products to end users. The company also sells directly or through distributors to hospitals, ambulatory surgery centers, and clinicians, especially for regenerative products used in surgical settings. Office-based physicians are important buyers for injection-based OA pain products, while hospitals and ASCs are the main users of implant and regenerative solutions. Internationally, Anika relies on commercial distributors that market and sell locally, making channel execution and partner performance central to demand generation.

- **OEM partner customers** (primary) — Large partners such as J&J MedTech buy HA-based OA products for resale and control downstream marketing and distribution.
- **Hospitals and ambulatory surgery centers** (primary) — These facilities buy regenerative and implantable orthopedic products for surgical procedures and inventory availability at point of care.
- **Office-based clinicians** (secondary) — Physicians and clinics buy injection-based OA pain products because they are used in outpatient treatment of osteoarthritis.
- **International distributors** (secondary) — Distributors buy products for local commercialization outside the U.S., supporting geographic expansion and market access.

- J&J MedTech, which buys Orthovisc and Monovisc for downstream resale
- Hospitals that use regenerative and surgical orthopedic products
- Ambulatory surgery centers that perform implant and orthopedic procedures
- Office-based clinicians who administer OA pain injections
- International distributors that buy products and market them locally
- Group purchasing organizations and integrated delivery networks that influence access

## Geography

Anika is headquartered in the United States and manufactures its global commercial supply from a single site in Bedford, Massachusetts. The U.S. is the most important operating market because it combines direct sales for regenerative products with OEM supply relationships for core OA products. Outside the U.S., the company relies on a worldwide distributor network to commercialize products in local markets, which reduces the need for a large direct-sales footprint but increases partner dependence. International sales growth was specifically cited as a driver of commercial channel growth in 2024, showing that non-U.S. markets matter to the growth strategy. Geography is operationally important because manufacturing concentration in one U.S. facility creates supply-chain and regulatory exposure, while international markets depend on local partner execution and reimbursement conditions.

- United States is the core market for OEM supply and direct regenerative sales
- Bedford, Massachusetts is the single manufacturing site for global commercial supply
- International revenue is supported by a worldwide distributor network
- Commercial channel growth has been driven partly by non-U.S. OA Pain Management sales
- U.S. hospitals and ASCs are key end markets for surgical products
- Single-site manufacturing increases operational concentration risk

## Strategy

Anika's current strategy is to focus on its OA Pain Management and Regenerative Solutions portfolios after divesting non-core businesses in 2024 and 2025. Management is prioritizing commercial execution, especially expanding the U.S. direct model for regenerative products and strengthening international distributor performance. The company is also investing in R&D and clinical trials for HA-based technologies, with emphasis on Cingal and Integrity, to support future product adoption and differentiation. Commercial infrastructure, market access, and logistics are being improved to support broader adoption across office-based, hospital, and ASC settings. This strategy is designed to reduce dependence on legacy channels, improve control over pricing and customer relationships, and reinforce the company’s HA technology platform.

- **Portfolio focus on core HA-based orthopedic products** (short-term) — Concentrating resources on the highest-value product families should improve execution and reduce distraction from non-core assets.
- **Build direct commercial capability in the U.S.** (medium-term) — Direct control over sales and market access can improve adoption, pricing discipline, and customer relationships for regenerative products.
- **Advance clinical and product development for HA technology** (medium-term) — Clinical evidence and product innovation are central to differentiation in a competitive orthopedic market.

- Concentrate on OA Pain Management and Regenerative Solutions after divestitures
- Expand direct U.S. commercial capabilities for regenerative products
- Support international growth through distributor relationships
- Invest in R&D and clinical trials for Cingal and Integrity
- Improve market access, logistics, and sales execution
- Reduce reliance on non-core product families and legacy channels

## Risks

Anika is exposed to concentration risk because a single customer, J&J MedTech, represented 50% of revenue in 2025, so any change in purchasing, pricing, or channel strategy could materially affect results. The company also relies on a single manufacturing site in Bedford, Massachusetts, which creates operational risk from equipment failure, quality issues, regulatory interruptions, or natural disasters. Competitive pressure is significant because orthopedic and OA pain products face established rivals, pricing pressure from hospitals and group purchasing organizations, and reimbursement-driven cost containment. Regulatory risk is meaningful because product approvals, labeling requirements, and compliance obligations can delay launches or restrict market access, especially for products like Hyalofast. In addition, product liability claims, inventory reserves, and dependence on third-party distributors can affect margins and cash flow when demand or channel execution weakens.

- **Dependence on J&J MedTech** [critical] — J&J MedTech accounted for 50% of revenue in 2025, so reduced orders or contract changes would have an outsized impact.
- **Single manufacturing site disruption** [high] — All global commercial supply is manufactured in Bedford, Massachusetts, so any interruption can halt supply and revenue.
- **Regulatory delays for Hyalofast and other products** [high] — Approval timing affects product launches, market access, and the ability to convert R&D spending into revenue.
- **Pricing and reimbursement pressure** [high] — Healthcare consolidation and payer pressure can force price concessions or restrict supplier access.
- **Product liability and quality claims** [medium] — Orthopedic implants and injectable products can generate claims if outcomes, safety, or manufacturing quality are challenged.

- Customer concentration with J&J MedTech creates revenue dependency
- Single-site manufacturing increases disruption and quality-control risk
- Pricing pressure from hospitals, GPOs, and integrated delivery networks
- Regulatory approval and compliance risk for new or existing products
- Product liability exposure typical for implantable and injectable devices
- Distributor execution risk outside the U.S.
- Inventory reserves can rise if demand or channel sell-through weakens

## Accounting

Revenue recognition is a key accounting issue because Anika sells through multiple models, including OEM supply, direct sales, distributor arrangements, and consignment inventory in surgical settings. For OEM contracts such as J&J MedTech, revenue depends on the contractual structure, transfer pricing, and variable consideration, while hospital and ASC sales are generally recognized at the date of surgical implantation rather than when inventory is placed on consignment. This means quarterly revenue can shift with procedure timing, channel inventory levels, and partner ordering patterns. Inventory reserves are also important because management disclosed higher inventory reserves as a driver of lower adjusted results in 2025, showing that excess or slow-moving stock can affect gross profit. In addition, goodwill, acquired in-process R&D, contingencies, and credit loss estimates require judgment and can materially affect reported earnings if assumptions change.

- **Revenue recognition across multiple channel models** — Can shift revenue between quarters and affect comparability
- **Inventory reserves** — Affects gross profit and operating margin
- **Goodwill and acquired in-process R&D** — Can create non-cash charges that materially affect earnings
- **Allowance for credit losses and contingencies** — Affects operating expenses and reported net income

- Revenue recognition differs across OEM, distributor, and direct sales models
- Consignment inventory delays revenue until implantation or end-user sale
- Variable consideration and partner contracts affect timing of recognized revenue
- Inventory reserves can materially affect gross profit and adjusted earnings
- Goodwill and acquired in-process R&D require impairment judgment
- Allowance for credit losses and contingencies depend on management estimates

---

*Last updated: 2026-08-11T04:46:20.953686+00:00*